Scarica l'app Stockscreener
58.49
0.46%
0.27
Dopo l'orario di chiusura:
58.23
-0.26
-0.44%
Precedente Chiudi:
$58.22
Aprire:
$58.45
Volume 24 ore:
766.30K
Relative Volume:
3.11
Capitalizzazione di mercato:
$4.45B
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+8.19%
1M Prestazione:
+7.48%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$54.50
$59.97
Intervallo di 1 settimana:
$51.23
$60.80
Portata 52W:
$9.95
$67.00
Jyong Biotech Ltd Stock (MENS) Company Profile
Nome
Jyong Biotech Ltd
Settore
Industria
Telefono
-
Indirizzo
-
Confronta MENS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MENS
Jyong Biotech Ltd
|
58.49 | 4.29B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Jyong Biotech Ltd Borsa (MENS) Ultime notizie
Jyong Biotech (NASDAQ:MENS) Shares Gap DownTime to Sell? - MarketBeat
Trump Sparks A 2025 IPO Boom: 5 New Stocks Have Rallied Over 400% - Benzinga
Jyong Biotech (NASDAQ:MENS) Stock Price Down 4.4%What's Next? - MarketBeat
Jyong Biotech (NASDAQ:MENS) Trading 6.5% HigherWhat's Next? - MarketBeat
Jyong Biotech (NASDAQ:MENS) Shares Down 8%What's Next? - MarketBeat
Jyong Biotech Wins Innovation Gold Award in Pharmaceutical Category at 2025 Taipei Biotech Awards - GlobeNewswire
First Taiwan-Developed Botanical Drug in FDA Phase III: Jyong Biotech Wins Gold for BPH Treatment - Stock Titan
Jyong Biotech (NASDAQ:MENS) Trading Down 6.1%Here's Why - MarketBeat
MENS Stock Price and Chart — NASDAQ:MENS - TradingView
Jyong Biotech (NASDAQ:MENS) Reaches New 52-Week HighStill a Buy? - MarketBeat
Jyong Biotech (NASDAQ:MENS) Shares Gap UpHere's Why - MarketBeat
Jyong Biotech Chairwoman and CEO Set to Attend as Speaker at 2025 Global Business Forum in Taipei - GlobeNewswire
Taiwan Biotech Leader Joins Global Business Forum: Jyong CEO to Discuss Cross-Border Innovation - Stock Titan
Jyong Biotech (NASDAQ:MENS) Stock Price Down 4.7%Should You Sell? - MarketBeat
Jyong Biotech completes patient enrollment in Phase II trial of MCS-8 - TipRanks
Jyong Biotech Announces Completion of Patient Enrollment of - GlobeNewswire
Jyong Biotech (NASDAQ:MENS) Sets New 12-Month HighHere's Why - MarketBeat
Enrollment goal met in trial of MCS-8 for prostate cancer prevention - Urology Times
Jyong Biotech completes phase II enrollment of 700+ patients for MCS-8 in prostate cancer prevention trial - MarketScreener
Jyong Biotech (MENS) Wraps Up Phase II Enrollment for Cancer Drug Study - GuruFocus
Jyong Biotech Completes Enrollment in Phase 2 Trial of Prostate Cancer Investigational Drug - MarketScreener
700+ Patient Milestone: Jyong Biotech's Prostate Cancer Prevention Drug Advances in Phase II Trial - Stock Titan
Jyong Biotech (NASDAQ:MENS) Trading Up 9.1%What's Next? - MarketBeat
Evaluating Jyong Biotech (NasdaqGM:MENS): What Recent Price Moves Reveal About Its Current Valuation - Yahoo Finance
Examining Jyong Biotech (NasdaqGM:MENS) Valuation Following Recent Share Price Momentum - simplywall.st
Shared decision-making: Clarifying roles in prostate cancer care - Urology Times
Biopharma IPO activity slows, but 2025 returns are surging - BioWorld MedTech
Jyong Biotech (NASDAQ:MENS) Sets New 52-Week HighStill a Buy? - MarketBeat
Jyong Biotech shares rise 1.06% premarket after being included in a stock market index. - AInvest
Experts discuss the transformative potential of AI for BPH - Urology Times
Timothy McClure, MD, on next steps for focal therapy in prostate cancer - Urology Times
Jennifer Robles, MD, on future advancements in HoLEP - Urology Times
Jyong Biotech to present clinical data from studies of BOTRESO, MCS-8 - MSN
Jyong Biotech (NASDAQ:MENS) Stock Price Down 6.7%What's Next? - MarketBeat
Jyong Biotech shares rise 1.83% after-hours after participating in the 22nd Urological Association of Asia Congress. - AInvest
Jyong Biotech shares fall 1.93% after-hours following participation in the 22nd Urological Association of Asia Congress. - AInvest
Jyong Biotech Ltd Azioni (MENS) Dati Finanziari
Non sono disponibili dati finanziari per Jyong Biotech Ltd (MENS). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):